Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE vs BRIXADI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Treatment of opioid dependence (Subutex, Suboxone),Moderate to severe pain (parenteral formulation, e.g., Buprenex),Off-label: Treatment of depression (as adjunctive therapy), chronic pain in opioid-tolerant patients, and neonatal abstinence syndrome (probable).
FDA-approved for the treatment of opioid use disorder (opioid dependence) as part of a comprehensive treatment plan
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Primarily hepatic via N-dealkylation to norbuprenorphine via CYP3A4, with minor contribution from CYP2C8; norbuprenorphine is active and further glucuronidated; undergoes extensive first-pass metabolism; mainly excreted in feces (as unchanged drug and metabolites) and to a lesser extent in urine.
Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite) via N-dealkylation; also undergoes glucuronidation.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Approximately 96% bound to alpha- and beta-globulins, with minimal binding to albumin.
Approximately 99% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Volume of distribution is 2-4 L/kg (mean ~3.2 L/kg). High Vd indicates extensive tissue distribution, including sequestration in brain and adipose tissue.
Volume of distribution is very large, approximately 500–1000 L (about 5–10 L/kg in a 70 kg individual), indicating extensive tissue binding and sequestration.
Sublingual: 30-55% (variable due to first-pass metabolism); Oral: ~15% (low due to extensive hepatic metabolism); Transdermal: ~15-20%; Intravenous/Intramuscular: 100%.
Intramuscular injection: bioavailability is nearly 100% due to limited first-pass metabolism; oral bioavailability is <5% due to extensive first-pass metabolism.
No dosage adjustment required for mild to moderate impairment (GFR >30 m L/min). For severe impairment (GFR <30 m L/min), consider reducing dose and increasing interval; avoid in anuric patients.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease, use with caution and consider dose reduction due to potential accumulation; specific dosing guidelines not established.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction).
Child-Pugh Class A (mild): No adjustment. Child-Pugh Class B (moderate): Start at lower dose and titrate cautiously; maximum recommended weekly dose 16 mg, monthly dose 96 mg. Child-Pugh Class C (severe): Not recommended due to lack of data.
For pain (≥2 years): sublingual tablet 2-6 mcg/kg every 4-8 hours; IV/IM 2-6 mcg/kg every 4-6 hours. For opioid use disorder (≥16 years): induction 2-4 mg, then titration to 12-16 mg once daily; safety in <16 years not established.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at lowest dose (e.g., sublingual 2 mg, transdermal 5 mcg/h) and titrate slowly due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment; monitor renal and hepatic function.
No specific dose adjustments recommended; geriatric patients may have increased sensitivity and should be monitored closely for sedation, respiratory depression, and QTc prolongation. Initiate at lower end of dosing range if severe renal or hepatic impairment present.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of serious harm or death with concomitant use of benzodiazepines or CNS depressants; requirement for patient access to emergency medical services and monitoring; risk of addiction, abuse, and misuse; risk of accidental exposure.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of harm or death from accidental ingestion; concomitant use of benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Respiratory depression: ceiling effect exists, but risk increases with non-opioid-tolerant use or coadministration of CNS depressants,Potentiation of respiratory depression by benzodiazepines and alcohol,Neonatal opioid withdrawal syndrome: avoid prolonged use during pregnancy unless necessary,Adrenal insufficiency: risk with prolonged use,Androgen deficiency: may occur with chronic use,Hypotension, especially in hypovolemic patients,Biliary tract spasm: may cause constriction of sphincter of Oddi,Risk of misuse, abuse, and diversion
May cause respiratory depression; risk of abuse potential; need to monitor for hepatic dysfunction; adrenal insufficiency; QT prolongation; precipitation of withdrawal if initiated too soon after full agonist opioids; impairment of mental/physical abilities.
Hypersensitivity to buprenorphine or any component of the formulation,Significant respiratory depression in non-opioid-tolerant patients,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction (including paralytic ileus),Monoamine oxidase inhibitor (MAOI) use within past 14 days (relative contraindication; may precipitate serotonin syndrome),Mild to moderate hepatic impairment: use with caution; severe hepatic impairment: contraindicated
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition. Avoid excessive alcohol. Maintain a balanced diet to support overall health during treatment.
No specific food interactions are reported for BRIXADI. However, patients should avoid alcohol and grapefruit juice as they may potentiate CNS depression or alter metabolism (grapefruit inhibits CYP3A4, which metabolizes buprenorphine, potentially increasing levels). Advise a balanced diet without restrictions beyond general health recommendations.
FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; may cause fetal respiratory depression if used near term.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
Buprenorphine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6 to 1.2. It is generally considered compatible with breastfeeding, but infants should be monitored for sedation and respiratory depression, especially in high maternal doses or with concomitant CNS depressants.
Unknown if excreted in human milk; no M/P ratio available. Consider risks and benefits; avoid breastfeeding if possible.
No routine dose adjustment is recommended, but dose may need to be increased due to increased clearance and volume of distribution in pregnancy, particularly in the third trimester. Monitor for withdrawal symptoms (e.g., craving, anxiety, abdominal cramping) and consider incremental dose increases (by 2-4 mg) if needed. Postpartum, dose should be titrated back to prepregnancy level over 1-2 weeks.
No standard dose adjustment; increased clearance in pregnancy may require dose titration to effect. Monitor for withdrawal or inadequate response.
Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu receptors, which can precipitate withdrawal if given to opioid-dependent patients already on full agonists. Sublingual administration avoids first-pass metabolism. Monitor liver function due to hepatotoxicity risk, especially with injectable forms. Long half-life allows every-other-day dosing in maintenance therapy. Naloxone is added in combination products to deter intravenous abuse.
BRIXADI (buprenorphine extended-release) is a monthly subcutaneous depot formulation for opioid use disorder (OUD). Initiate only after patient is stabilized on transmucosal buprenorphine (e.g., 8–24 mg/day for at least 7 days). Do not use in opioid-naive patients due to risk of precipitated withdrawal. Administer subcutaneously in the abdomen; avoid intramuscular or intravenous injection. Monitor injection site for nodules, granulomas, or infection. Concomitant use with benzodiazepines or CNS depressants requires careful monitoring due to additive respiratory depression. Liver function tests should be monitored periodically due to risk of hepatic injury. BRIXADI contains buprenorphine as the free base, not salt; dose strengths (64 mg, 96 mg, 128 mg) are not equivalent to other buprenorphine formulations. Upon discontinuation, patients may experience prolonged withdrawal due to slow release over weeks.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not use alcohol, benzodiazepines, or other sedatives while on buprenorphine as it can cause severe drowsiness, respiratory depression, or coma.,Avoid driving or operating heavy machinery until you know how buprenorphine affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store safely out of reach of children; accidental ingestion can be fatal.,Inform your doctor if you have liver disease, breathing problems, or are pregnant.,If you miss a dose, take it as soon as possible; skip if almost time for next dose. Do not double dose.
BRIXADI is a once-monthly injection to treat opioid dependence and must be given by a healthcare provider only.,Do not attempt to self-administer or remove the injection. The medicine is released slowly over one month.,Notify your doctor immediately if you have trouble breathing, excessive drowsiness, or severe dizziness, especially when combined with alcohol or sedatives.,Avoid use of other opioids (prescription or illicit), as serious side effects including coma or death may occur.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea, or abdominal pain.,The injection site may become red, swollen, or painful; contact your doctor if these persist or worsen.,Do not stop BRIXADI suddenly; withdrawal symptoms may occur and can be prolonged.,Keep out of reach of children and pets; accidental exposure can be fatal.
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE vs BRIXADI, answered by our medical review team.
BUPRENORPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.. BRIXADI is a Opioid Partial Agonist that works by Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE and BRIXADI depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE is: Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.. The standard adult dose of BRIXADI is: Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE and BRIXADI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE is classified as Category C. FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal ano. BRIXADI is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.